DSGN — Design Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1807120 ·
Last close
$9.84
Market Cap
$630.12M
52W High
$17.25
52W Low
$7.25
ADV30
422,203
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -22,230,000 -20,288,000 216,808,000 15,252,000 14,612,000
Jun 2026 0 — -22,177,000 -20,165,000 215,129,000 12,907,000 13,271,000
Mar 2026 0 — -19,706,000 -17,636,000 230,442,000 12,770,000 12,388,000
Dec 2025 0 — -18,169,000 -15,997,000 226,203,000 16,856,000 13,700,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-59,299,000
Investing CF
$-3,927,000
Financing CF
$63,390,000
CapEx
$-208,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.20
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-355,095,000
Inventory
—
Receivables
$1,743,000
ST Investments
$193,356,000
EBIT TTM
$-82,282,000
Pretax Income TTM
$-74,086,000
Interest Exp TTM
—
Analysts
7

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -79,467,000 -69,792,000 226,203,000 13,700,000 212,503,000 -54,358,000
Dec 2024 0 -62,383,000 -49,588,000 252,093,000 9,996,000 242,097,000 -43,105,000
Dec 2023 0 -78,190,000 -66,862,000 289,643,000 11,956,000 277,687,000 -58,560,000
Dec 2022 0 -67,593,000 -63,308,000 341,137,000 13,827,000 327,310,000 -51,317,000

TTM Snapshot

Revenues TTM
$8,568,000
NetIncome TTM
$-70,795,000
OpCashFlow TTM
—
Assets (Latest)
$215,129,000
Forward EPS
$-1.62

Max Pain — expiry 2026-12-18

max pain strike: $10.00 · spot: $9.47 · call oi: 20,394 · put oi: 27
Expected Move to 2026-12-18: ±$2.95 (31.15%) — implied range $6.52 – $12.42 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ALMS ALUMIS INC. $628.33M $4.84 —
OLMA Olema Oncology, Inc. $632.52M $7.22 —
BCAX Bicara Therapeutics Inc. $637.32M $9.60 —
ABUS Arbutus Biopharma Corp $620.84M $4.05 —
SVA SINOVAC BIOTECH LTD $642.44M $6.47 —

News headlines (Yahoo Finance, 1h cache)

Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates
2026-11-04 21:01 · Yahoo
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
2026-05-18 11:00 · Yahoo
Design Therapeutics Inc (DSGN) Q1 2026 Earnings Call Highlights: Promising Progress in ...
2026-04-29 23:00 · Yahoo
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
2026-05-11 16:00 · Yahoo
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
2026-05-17 20:00 · Yahoo
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
2026-05-28 12:00 · Yahoo
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
2026-04-28 20:01 · Yahoo
Design Therapeutics Q1 Earnings Call Highlights
2026-04-29 09:04 · Yahoo
Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN)
2026-05-18 14:02 · Yahoo
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch
2026-08-27 14:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.